Cisplatin and Nano-particle Formulations of Cisplatin for Cancer Therapy: A Review
Popsy Raj
Department of Pharmaceutics, K. R. Mangalam University, Haryana, India.
Bharat Lal *
Department of Pharmaceutics, K. R. Mangalam University, Haryana, India.
Manoj Gadewar
Department of Pharmaceutics, K. R. Mangalam University, Haryana, India.
Anita Singh
Sunder Deep Pharmacy Collage, Ghaziabad, India.
G. K. Prashanth
Department of Chemistry, Sir M. Visvesvaraya Institute of Technology, Bengaluru, India.
*Author to whom correspondence should be addressed.
Abstract
Cisplatin (cis-(diammine)dichloridoplatinum(II)) is the first platinum-based compound approved by the United States Food and Drug Administration (FDA) (U.S.). This is a first-line chemotherapeutic treatment used alone or combined with other anticancer drugs to treat a broad spectrum of malignancies, with cisplatin-based nano-formulations currently in clinical studies. Cisplatin has several drawbacks, including low aqueous solubility, drug resistance, and toxicity, all of which can be addressed by encapsulating the drug in Nemours nanocarriers. The various nano-delivery technologies developed for Cisplatin are covered in vast literature from different electronic databases. This review focuses on comparative findings over the recent advancements, developments, innovations, and updated literature for various CDDP nano-carrier systems.
Keywords: Cancer, cisplatin, nano-technology, nano-formulation, food, drug administration